Pregnenolone in the treatment of women with chronic schizophrenia

Phase 4

• Conditions: schizophrenia.; schizophrenia

• Registration Number: IRCT201504211556N76
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

1-women with Diagnosis of Schizophrenia based on DSM- 5 criteria; 2- Minimum Score of 60 on Positive and Negative Scale; 3- Age between 18-45; 4-Chronic Schizophrenia- duration of the disorder more than 2 years; 5-Minimum score of 20 in negative sub score. Exclusion criteria: 1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4-receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month; 5-receiving ECT during the last 14 days ; 6-Hepatic and renal diseases; 7- History of thromboembolism ; 8- History of abnormal uterine bleeding, uterine or breast canser; 9-CVA; 10-Hormone replacement therapy; 11- Endocrine abnormality.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).